In this context, our discovery of the LR/CHEK1 axis as a novel mechanism of miltefosine underlies its preferential cytotoxicity on cancer cells and will help convince the rationale for the further development of APL drugs for cancer treatment. Here, CHEK1 is linked to acute promyelocytic leukemia.